Genomic PCR will be tested extensively as a convenient and preferred tool for detecting biomarkers of genomic abnormalities. After confirmation on ex vivo expanded CTCs, optimal PCR settings will be established and tested for detection of CTCs directly from blood samples, first from the blood of mice …show more content…
The aCGH assay will be an essential tool to assess the genomic changes. Based on the results of SKY and aCGH analyses, representative CTC cultures will be subjected to mutation screening in CTC, CTD-PDX and biopsy materials by whole genome sequencing using NGS for comprehensive molecular profiling of abnormalities at the nucleotide level. NGS data will be transferred to Palanisamy, who will carry out biostatistics and bioinformatics analysis. Given the unbiased nature of NGS analysis, we anticipate identifying new druggable genomic mutations on a personalized